CHIRAL POOL SYNTHESIS OF 8-HYDROXYMETHYL-"9-OXA"-ANTHRACYCLINONES

Hanh Dufat-Trinh Van, François Tillequin, Claude Monneret, and Michel Koch\* Departement de Pharmacognosie associé au CNRS, UA n°484, Faculté de Pharmacie, 4 avenue de l'Observatoire, 75270 Paris Cedex O6, France

<u>Abstract</u> - The synthesis of title compounds from (R)-2,3-0-isopropylideneglyceraldehyde and leucoquinizarin is reported.

Doxorubicin  $(\underline{1})$  and daunorubicin  $(\underline{2})$  are glycoside antibiotics widely used in the chemotherapic treatment of different human cancers<sup>1</sup>.



1 R = OHR = H5 R≃ H or sugar R ≃ H R = g (N-dimethylacosamine) On the other hand, different pyranonaphthoquinone antibiotics including kalafungin (3) or its enantiomer nanaomycin D and closely related nanaomycin A have been shown to possess significant antimicrobiological properties<sup>2</sup>. It has also been postulated that these compounds would possess some antineoplastic activities as bioreductive alkylating agents<sup>3</sup>. This has been supported by the recent discovery of lactoquinomycin (4)<sup>4</sup>, an amino-glycoside of kalafungin which displayed antitumor activity although its mechanism of action has not yet been reported. Synthesis of new analogs of 1 and 2 with an oxygen in the A ring instead of both the side-chain and axial OH at C-9 and with a hydroxymethyl side-chain at C-8 such as the 5,12-dihydroxy-3-hydroxymethyl-3,4-dihydro-1H-anthra[2,3-c]pyran-6,11dione (R = H), has been undertaken. Intercalation with native DNA must be less

marked with these new glycosides of general formula 5 than with 1 and 2 since it

has been shown on different models<sup>5</sup> that 9-OH and 13 C=O strongly participate but, in contrast, they could act as more powerful alkylating agent after bioreduction $^{3}$ . A synthetic strategy to elaborate such a tetracyclic skeleton followed the general A + BCD route which has been already successfully used in our laboratory $^{6}$ . With the same goal in mind to synthesize enantiomerically pure compounds to avoid the complex and wasteful separation of diastereoisomers after glycosidation with loss of the valuable amino-sugar moiety, (R)-2,3-0-isopropylideneglyceraldehyde (6) was used as chiral precursor  $^7$  of ring A. Aldol condensation of this latter with anion of leucoquinizarin (7), precursor of rings BCD could be a possible way to obtain under Marschalk conditions<sup>8</sup> and in the first step, a chiral  $\beta$ -alkylanthraquinone. Since this reaction gave three products in a temperature-dependent ratio, efforts were directed towards conditions which gave the desired compound 8 as major product. Thus at 40°C, 8 (m p 149-152°C;  $\left[\alpha\right]_{D}^{20}$  -40° in CH<sub>2</sub>Cl<sub>2</sub>)<sup>9</sup> was isolated in 46 % yield along with a small amount of the corresponding hydroxyderivative ( $\underline{9}$ ) (mixture of diastereoisomers<sup>10</sup>, 7 %) and 24 % of 10 (m p 143-145°C)<sup>11</sup>. A second alkylation of 8 under Marschalk conditions with formaldehyde at room temperature for 1 h, afforded <u>11</u> (m p 149°C;  $[\alpha]_{D}^{20}$  -122° in CH<sub>2</sub>Cl<sub>2</sub>) which was isolated in 98 % yield.



Photochemical bromination of <u>11</u> (NBS, 2,2'-azobis(2-methylpropanenitrile),  $CCl_4$ , 2 h) led to <u>13</u> in 20 % yield (m p 105°C,  $[\alpha]_D^{20}$  -106° in  $CH_2Cl_2$ ) along with the mixture of compounds <u>14</u> resulting from bromination of one of the two methyl groups of the acetal ring. Owing to this difficulties, in a further attempt, the acetal ring of <u>11</u> was removed under acidic conditions (1N HCl-MeOH, room temperature, 2 h) to give <u>15</u> in quantitative yield (m p 174°C;  $[\alpha]_D^{20}$  -107° in MeOH). After peracetylation of <u>15</u> (Ac<sub>2</sub>0, C<sub>5</sub>H<sub>5</sub>N, room temperature, 48 h), giving <u>16</u> (m p 135°C;  $[\alpha]_D^{20}$  +33° in CHCl<sub>3</sub>) in quantitative yield, benzylic bromination was performed by irradiation of <u>16</u> (1,3-dibromo-5,5' -dimethylhydantoin, CCl<sub>4</sub>, 2 h)<sup>12</sup> to obtain <u>19</u> (m p 140°C) in 77 % yield. On the other hand, ortho-dialkylquinizarin (12) must be prepared in a way different from that previously used to synthesize 11 since Marschalk condensation of 8 with CH<sub>3</sub>CHO led to 21 (m p 148-150°C). Nevertheless, 12 (m p 158°C;  $[\alpha]_D^{20}$ -50° in CH<sub>2</sub>Cl<sub>2</sub>) could be obtained in 16 % yield starting from 2-ethylquinizarin (22) by aldol condensation with (R)-2,3-0-isopropylideneglyceraldehyde. Access to 20 (mixture of diastereoisomers) involved the same sequence of reactions as that previously used for the synthesis of 19:i) cleavage of the acetal ring , ii) peracetylation , iii) photochemical bromination (12  $\rightarrow$  17  $\rightarrow$  18  $\rightarrow$  20).



Heating <u>19</u> under reflux in a methanolic solution previously saturated with HCl gas gave quantitatively the required aglycon  $(\underline{23})^{13}$  (m p 190°C;  $[\alpha]_D^{20}$  -139° in CHCl<sub>3</sub>). The same reaction applied to <u>20</u> led in 60 % overall yield to an equimole-cular mixture of diastereoisomers  $\underline{24}^{14}$  (m p 200°C;  $[\alpha]_D^{20}$  -113° in CHCl<sub>3</sub>) and  $\underline{25}^{15}$  (m p 238°C;  $[\alpha]_D^{20} + 20°$  in CHCl<sub>3</sub>) easily separated after column chromatography (silica gel, CH<sub>2</sub>Cl<sub>2</sub>). The absolute configuration at C-1 of both compounds could be established from their <sup>13</sup>C nmr spectra. The spectrum of <u>24</u> exhibits two aliphatic <u>CH</u> signals at 71.8 and 73.3 ppm which correspond to the presence of two pseudo-axial substituents at C-3 and C-1 whereas the corresponding signals located at 65.8 and 68.3 ppm for <u>25</u> indicate a pseudo-axial and a pseudo-equatorial substituent on the A ring. Furthermore, these latter values were in good agreement

with the data published for nanaomycin  $A^{16}$ . From these spectra, it could be deduced that the configurations were (1S,3S) for <u>24</u> and (1R,3S) for <u>25</u>



Several glycoside derivatives with amino-deoxy-sugar or deoxy-sugar have been prepared with both new aglycons. They have shown no significant antibiotic or antitumour activity and details for their preparation and for biological results will be reported later on.

ACKNOWLEDGMENTS

We are grateful to Hoechst Laboratories (Paris) for financial support. REFERENCES AND NOTES

- F. Arcamone, Doxorubicin Anticancer Antibiotics, Academic Press, New York, 1981; F. Arcamone, <u>Med. Res. Rev.</u>, 1984, 4, 153.
- H. Tanaka, Y. Koyama, J. Awaya, H. Marumo, R. Oiwa, M. Katagiri, T. Nagai and S. Omura, J. Antibiot., 1975, 28, 860.
- 3. H.W. Moore, <u>Science</u>, 1977, 1927, 527.
- 4. N. Tanaka, T. Okabe, F. Isono, M. Kashiwagi, K. Nomoto, M. Takahashi,
  A. Shimazu and T. Nishimura, <u>J. Antibiot.</u>, 1985, <u>38</u>, 1327; T. Okabe, K. Nomoto,
  H. Funabashi, S. Okuda, H. Suzuki and N. Tanaka, <u>J. Antibiot.</u>, 1985, <u>38</u>, 1333.
- W.J. Pigram, W. Fuller and L.D. Hamilton, <u>Nature New Biology</u>, 1972, 235, 17.
   G.J. Quigley, A.H.J. Wang, G. Ughetto, G. Van Der Marel, J.H. Van Boom and A. Rich, <u>Proc. Natl. Acad. Sci. USA</u>, 1980, <u>77</u>, 7204.
- 6. F. Bennani, J.C. Florent, M. Koch and C. Monneret, Tetrahedron, 1984, 40, 4669.
- For use of (R)- and (S)-2,3-O-isopropylideneglyceraldehyde in organic synthesis, see : J. Jurczak, S. Pikyl and T. Bauer, <u>Tetrahedron</u>, 1986, 42, 447.
- 8. C. Marschalk, F. Koenig and N. Ouroussoff, Bull. Soc. Chim. Fr., 1936, 1545.
- 9. All new compounds gave i.r., n.m.r., m.s. and h.r.m.s. or combustion analysis consistent with their assigned structures.
- 10. Since the 7-OH (anthracycline numbering) as present in 9 was not required for

the present synthesis, the stereochemical course of the reaction was not determined.

11. The formation of 10 can be explained by the following mechanism :



- 12. D. Dominguez, R.J. Ardecky and M.P. Cava, <u>J. Am. Chem. Soc.</u>, 1983, 105, 1608.
  13. 5,12-dihydroxy-3-hydroxymethyl-3,4-dihydro-1H-anthra [2,3-c] pyran-6,11-dione (23): C<sub>18</sub>H<sub>14</sub>O<sub>6</sub>; <sup>1</sup>H n.m.r. (CDC1<sub>3</sub>, TMS)<sub>6</sub> ppm : 13.67 and 13.62 (2 x 1H, 2s, D<sub>2</sub>O exch., OH-5, OH-12), 8.37 (2H, m, H-7, H-10), 7.84 (2H, m, H-8, H-9), 4.93 (1H, d, J = 10Hz, H-1a), 4.87 (1H, d, J = 10Hz, H-1b), 4.13 (1H, m, H-3), 3.78 (1H, dd, J = 11Hz, J'= 4Hz) and 3.60 (1H, dd, J = 11Hz, J'= 6Hz)(<u>CH<sub>2</sub>OH</u>), 3.18 (1H, dd, J = 14Hz, J'= 5Hz, H-4a), 2.89 (1H, dd, J = 14Hz, J'= 8Hz, H-4b), 2.53 (1H, br s, D<sub>2</sub>O exch., CH<sub>2</sub>OH).
- 14. (1S,3S)-5,12-dihydroxy-3-hydroxymethyl-1-methyl-3,4-dihydro-1H-anthra[2,3-c]pyran-6,11-dione (24) :  $C_{19}H_{16}O_6$ ; <sup>1</sup>H n.m.r. (CDCl<sub>3</sub>, TMS)  $\delta$  ppm : 16.42 and 15.98 (2 x 1H, 2s, D<sub>2</sub>O exch., OH-5, OH-12), 8.35 (2H, m, H-7, H-10), 7.82 (2H, m, H-8, H-9), 5.13 (q, J = 6Hz, H-1), 3.87 (1H, m, H-3), 3.73 (2H, m, CH<sub>2</sub>OH), 2.91 (1H, dd, J = 17Hz, J'= 2Hz, H-4a), 2.60 (1H, dd, J = 17Hz, J'= 10Hz, H-4b), 2.15 (1H, br s, D<sub>2</sub>O exch., CH<sub>2</sub>OH), 1.58 (3H, d, J = 6Hz, CH<sub>3</sub>).
- 15. (1R,3S)-S,12-dihydroxy-3-hydroxymethyl-1-methyl-3,4-dihydro-1H-anthra[2,3-c]
  pyran-6,11-dione (25) : C<sub>19</sub>H<sub>16</sub>O<sub>6</sub> ; <sup>1</sup>H n.m.r. (CDCl<sub>3</sub>, TMS) s ppm:16.20 and 16.07
  (2 x 1H, 2s, D<sub>2</sub>O exch., OH-5, OH-12), 8.35 (2H, m, H-7, H-10), 7.82 (2H, m,
  H-8, H-9), 5.27 (q, J = 7Hz, H-1), 4.11 (1H, m, H-3), 3.87 (1H, dd, J = 11Hz,
  J'= 2 Hz) and 3.71 (1H, dd, J = 11Hz, J'= 7Hz)(CH<sub>2</sub>OH), 2.87 (1H, dd, J = 18Hz,
  J'= 4Hz, H-4a), 2.60 (1H, dd, J = 18Hz, J'= 11Hz, H-4b), 2.11 (1H, br s,
  D<sub>2</sub>O exch., CH<sub>2</sub>OH), 1.64 (3H, J = 7Hz, CH<sub>3</sub>).
- H. Tanaka, Y. Koyama, T. Nagai, H. Marumo and S. Omura, <u>J. Antibiot.</u>, 1975, <u>28</u>, 868.

Received, 24th September, 1986